<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04681534</url>
  </required_header>
  <id_info>
    <org_study_id>NWK_AlphaDBS_FIM_2019</org_study_id>
    <nct_id>NCT04681534</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Adaptive Deep Brain Stimulation</brief_title>
  <official_title>A Double-blind Crossover Study to Evaluate the Safety and Efficacy of Adaptive Deep Brain Stimulation Delivered Through AlphaDBS System in Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Newronika</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Newronika</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the safety and the potential efficacy of personalized&#xD;
      Local Field Potential (LFP)-based adaptive Deep Brain Stimulation (aDBS), using the&#xD;
      implantable pulse generator (IPG) of the &quot;AlphaDBS&quot; System, in Parkinson's Disease patients,&#xD;
      chronically implanted in subthalamic nucleus (STN) for DBS, at the time of IPG replacement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study protocol is organized in two phases: the &quot;short-term follow-up&quot; and the &quot;long-term&#xD;
      follow-up&quot;.&#xD;
&#xD;
      PD patients in need of IPG replacement will be screened for enrollment eligibility.&#xD;
&#xD;
      For the &quot;short-term follow-up&quot;, randomized patients will undergo 2 days of experimental&#xD;
      sessions (i.e. one per each type of stimulation mode, cDBS and aDBS), in a well-controlled&#xD;
      environment (i.e. during hospitalization). This part of the study will collect information on&#xD;
      safety and potential efficacy endpoints as assessed by experienced neurologists. The &quot;short&#xD;
      term follow-up&quot; phase will be considered complete when the endpoint assessment has been&#xD;
      performed for all patients.&#xD;
&#xD;
      Patients, who will not experience severe side effects and who will be deemed suitable by the&#xD;
      neurologist, will be eligible to continue in the &quot;long-term follow-up&quot; phase (i.e. 1 month)&#xD;
      in their &quot;home&quot; environment. The &quot;AlphaDBS&quot; System will deliver the stimulation in aDBS or&#xD;
      cDBS mode, for two weeks in each mode.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of the &quot;AlphaDBS&quot; System, when used in cDBS and aDBS mode</measure>
    <time_frame>1 month</time_frame>
    <description>Occurrence of device related adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the TEED to the patient</measure>
    <time_frame>1 month</time_frame>
    <description>Change in the Total Electrical Energy Delivered (TEED) to the patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PD-related motor symptoms and their fluctuations</measure>
    <time_frame>1 month</time_frame>
    <description>Evaluation of PD-related motor symptoms using the Unified Parkinson's Disease Rating Scale - UPDRS Part III.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyskinesia</measure>
    <time_frame>1 month</time_frame>
    <description>Evaluation of dyskinesia and their fluctuations through repeated clinical assessments using the Unified Dyskinesia Rating Scale - UDysRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyskinesia</measure>
    <time_frame>up to 1 month</time_frame>
    <description>Evaluation of the performance of a wearable accelerometer in detecting dyskinesia (compared to patient reported dyskinesia in the patient diary)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&quot;Time on&quot; with and without dyskinesia</measure>
    <time_frame>1 month</time_frame>
    <description>Evaluation of &quot;time on&quot; with and without dyskinesia, assessed through Patient Diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&quot;Time off&quot;</measure>
    <time_frame>1 month</time_frame>
    <description>Evaluation of &quot;time off&quot;, assessed through Patient Diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient controller usability</measure>
    <time_frame>1 month</time_frame>
    <description>Usability will be evaluated by means of a usability questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usability of the system for the physician</measure>
    <time_frame>1 month</time_frame>
    <description>Usability will be evaluated by means of a usability questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>conventional DBS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>adaptive DBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AlphaDBS System</intervention_name>
    <description>AlphaDBS can be programmed with two different types of stimulation: conventional DBS and adaptive DBS, that automatically adjusts the energy delivered to patient using a biosignal, local field potential (LFP), in a close loop configuration.</description>
    <arm_group_label>adaptive DBS</arm_group_label>
    <arm_group_label>conventional DBS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of idiopathic PD;&#xD;
&#xD;
          2. Subject is bilaterally treated with DBS in the STN using a Medtronic Activa PC or&#xD;
             Activa RC IPG (mono-channnel or dual channel);&#xD;
&#xD;
          3. DBS implant for at least 3 years and in need of battery replacement within 12 months&#xD;
             after consent;&#xD;
&#xD;
          4. Patients must be able to understand and sign the informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with severe cognitive decline, as resulting from MoCA assessment (MoCA score&#xD;
             &lt; 10);&#xD;
&#xD;
          2. Patients with major psychiatric issues or any other condition that, based on the&#xD;
             physician opinion, could interfere with the study conduct (e.g. severe depression,&#xD;
             psychosis, etc.);&#xD;
&#xD;
          3. Patients with any medical conditions potentially interfering with DBS battery&#xD;
             replacement surgery (e.g. severe hypertension, active cancer, intake of drugs&#xD;
             interfering with the coagulation etc.);&#xD;
&#xD;
          4. Need to replace or reposition the leads during the IPG replacement procedure;&#xD;
&#xD;
          5. Patients with &gt; 10 recurrent falls experienced in the 3 months prior to consent;&#xD;
&#xD;
          6. Patients that cannot tolerate an interruption of DBS stimulation for at least 30 min;&#xD;
&#xD;
          7. Patients taking less than one levodopa dose per day;&#xD;
&#xD;
          8. Patients without suitable LFPs recordings or with significant artifacts;&#xD;
&#xD;
          9. Pregnant or breastfeeding women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Costanza Conti, PhD</last_name>
    <phone>+39 02 84 109 381</phone>
    <email>costanza.conti@newronika.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elena Pirola, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Neurologico Carlo Besta</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Eleopra, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Citt√† della Salute e della Scienza di Torino</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Lanotte, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Copernicus Podmiot Leczniczy</name>
      <address>
        <city>Gda≈Ñsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Witold Libionka, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sk≈Çodowskiej-Curie - Pa≈Ñstwowy Instytut Badawczy</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomasz Mandat, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 20, 2020</study_first_submitted>
  <study_first_submitted_qc>December 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

